Moderna, Inc.

MRNA · NasdaqGS · Stock · Healthcare
$223.25
+3.24% today
Delayed price,

What Moderna does

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Key facts

Sector
Healthcare
Industry
Biotechnology
Market cap
$89.13B
P/E (ttm)
—
Forward P/E
-50.3
Dividend yield
0.00%
Beta
1.09
Profit margin
-141.4%
Employees
4,700
Headquarters
Cambridge, MA, United States
Exchange
NasdaqGS

Performance

1 Month
+44.9%
3 Months
+261.1%
6 Months
+315.6%
1 Year
+758.3%
5 Years
-36.7%
$22.2852-week range$227.46
Biggest setback — last 12 months
-32.2%
29 Jun 2026 → 20 Jul 2026
Fell from $79.76 to $54.07 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+848.6%
17 Nov 2025 → 5 Oct 2026
Ran from $23.72 to $225.00 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$144.79 (-35.1%)$223.25$344.23 (+54.2%)
3 Months$105.46 (-52.8%)$223.25$472.62 (+111.7%)
6 Months$77.30 (-65.4%)$223.25$644.81 (+188.8%)
12 Months$49.81 (-77.7%)$223.25$1,000.54 (+348.2%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 150.0%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Sold 2,158 shares at $190.01 — Mock James M, Chief Financial Officer · 2026-10-07
Sold 233,480 shares at $146.07 — Hoge Stephen, President · 2026-09-16
Sold 54,672 shares at $134.49 — Mock James M, Chief Financial Officer · 2026-09-14
Sold 17,501 shares at $148.87 — Mock James M, Chief Financial Officer · 2026-09-08
Sold 17,501 shares at $148.87 — Klinger Shannon Thyme, Chief Legal Officer · 2026-09-08
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.